ketamine-enhanced prolonged exposure

PreclinicalSmall molecule

MMinneapolis Veterans Affairs Medical Center

ketamine-enhanced prolonged exposure is one of 4 small molecule programs targeting Prolonged. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ProlongedCompleted

ProlongedPreclinical

Completed

Competition

Competitive Landscape

4 competitors in Prolonged

#DrugCompanyPhaseTrials

Angiomax

BBaxter Healthcare Corporation

Preclinical

2 2

Xatral XL

IInternational Bio service

Phase 1

1 3

Alfuzosin Hydrochloride

UUniversity of Minnesota

Phase 1

1 4

ketamine-enhanced prolonged exposure

MMinneapolis Veterans Affairs Medical Center

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Post-Traumatic Stress Disorder1 trial

Repeated Sub-anesthetic Ketamine to Enhance Prolonged Exposure Therapy in Post-traumatic Stress Disorder: A Proof-of-concept Study

Completed·MMinneapolis Veterans Affairs Medical Center·Preclinical·NCT03960658·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ketamine-enhanced prolonged exposure. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ketamine-enhanced prolonged exposure compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ketamine-enhanced prolonged exposure. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Minneapolis Veterans Affairs Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMinneapolis Veterans Affairs Medical Center

ketamine-enhanced prolonged exposure

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Post-Traumatic Stress Disorder1 trial

References

Drug Info

Quick Facts

Related News